Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Consensus PT from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $41.44.

Several equities research analysts have weighed in on ARWR shares. Royal Bank of Canada reissued an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. B. Riley reissued a “buy” rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th.

Arrowhead Pharmaceuticals Stock Down 7.8 %

Shares of Arrowhead Pharmaceuticals stock opened at $12.74 on Thursday. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market cap of $1.75 billion, a P/E ratio of -2.46 and a beta of 0.92. The firm’s 50 day moving average price is $17.99 and its 200-day moving average price is $19.55. Arrowhead Pharmaceuticals has a 52-week low of $12.14 and a 52-week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, sell-side analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 11,520 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00. Following the sale, the chief executive officer now directly owns 3,764,252 shares in the company, valued at $71,709,000.60. This trade represents a 0.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the completion of the transaction, the chief financial officer now directly owns 473,433 shares of the company’s stock, valued at $9,388,176.39. The trade was a 5.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 286,317 shares of company stock valued at $5,049,735 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Mackenzie Financial Corp acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $137,000. GF Fund Management CO. LTD. purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at about $49,000. Neo Ivy Capital Management acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth about $318,000. Two Sigma Advisers LP increased its stake in Arrowhead Pharmaceuticals by 330.7% during the 4th quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company’s stock worth $8,097,000 after buying an additional 330,700 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Arrowhead Pharmaceuticals by 281.3% during the fourth quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company’s stock valued at $14,934,000 after acquiring an additional 586,062 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.